Skip to main content
. 2021 Nov 16;41(5):1349–1357. doi: 10.1007/s10067-021-05980-5

Table 3.

Clinical-epidemiological characteristics of patients with SLE immunized against SARS-CoV-2

Variables Total (N = 100)
Age, years 35 (27.5–49)
Sex - n (%)

Female

Male

94 (94%)

6 (6%)

Time of illness (SLE), years 7.5 (4–13)

Comorbidities*

Hypothyroidism

Chronic kidney disease

APS

Arterial hypertension

Rheumatoid arthritis

Sjögren’s syndrome

Others

55 (55%)

15 (15%)

13 (13%)

7 (7%)

7 (7%)

6 (6%)

5 (5%)

20 (20%)

Associated commitment of SLEǂ

Articulate

Renal

Dermal

Hematological

Mucocutaneous

Pulmonary

Neurological

Cardiovascular

74 (74%)

60 (60%)

23 (23%)

21 (21%)

17 (17%)

15 (15%)

15 (15%)

4 (4%)

Usual treatment of SLE Inline graphic

Prednisone

Hydroxychloroquine

Azathioprine

Mycophenolate

Methotrexate

Cyclophosphamide

Leflunomide

Cyclosporine

No treatment

71 (71%)

75 (75%)

24 (24%)

23 (23%)

8 (8%)

5 (5%)

2 (2%)

1 (1%)

9 (9%)

COVID-19 background

Yes

No

39 (39%)

61 (61%)

Hospitalization for COVID-19 3 (3%)
SLE reactivation in the last 6 months (documented by rheumatologist physician) 28 (28%)

Data are n (%) or median (IQR).

*12 patients presented 2 or more comorbidities

APS antiphospholipid syndrome

‡Juvenile idiopathic arthritis (1), avascular necrosis (1), primary biliary cirrhosis (1), diabetes (2), transverse myelitis (1), fibromyalgia (4), pulmonary fibrosis (2), glaucoma (2), asthma (1), aortic stenosis (1), hepatitis C (2), celiac disease (1), pregnancy (1)

ǂ70 patients had 2 or more systems affected by SLE

Inline graphic 72 patients were taking 2 or more drugs